# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frida Kahlo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI011-SYN
- Date: 2026-10-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Ortega, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week chronic pain follow-up and first opioid dose reduction. **S**

## History of present illness

Ms. Kahlo returns four weeks after her first visit. The cold she had last week has cleared. She has gone to physical therapy twice a week, missing one aquatic session while she was ill, and wears the new shoe lift. On duloxetine 60 mg for two weeks she has had no nausea, sweating, or dizziness. The burning in her right leg is less, and she now stands at the easel for about 20 minutes. She has kept to no more than four oxycodone tablets a day and on most days takes three or four. She is ready for the first dose reduction she agreed to two weeks ago, and she starts weekly cognitive behavioral therapy for chronic pain today. **S**

| Element | Detail |
|---|---|
| Recent illness | Common cold last week, cleared |
| Rehabilitation | Physical therapy twice weekly; one session missed while ill; shoe lift in use |
| Duloxetine 60 mg | Two weeks, no side effects |
| Function | Stands at the easel for about 20 minutes |
| Opioid use | Three or four oxycodone tablets on most days; never more than four |
| Taper | Ready for the agreed first reduction |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or drowsiness |
| Respiratory | Negative | Cough gone |
| Gastrointestinal | Negative | No nausea or constipation |
| Musculoskeletal | Positive | Back and pelvic pain, easing; right ankle pain on standing; no falls |
| Neurological | Positive | Less burning in the right leg; no new weakness; no bladder or bowel control change |
| Psychiatric | Negative | Mood better; PHQ-9 score 6 with item 9 scored 0 |

6 systems reviewed. **S**

## Current medications

- Oxycodone 10 mg oral tablet, one tablet three times daily as needed for pain **S**
- Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for pain **S**
- Duloxetine 60 mg delayed-release oral capsule, one capsule daily **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily **S**
- Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily **S**
- Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 50.5 kg; BMI 19.7 kg/m². All vital signs are synthetic.

PEG pain and function score (0-10): 6; PHQ-9: 6. All results are synthetic.

## Change since baseline

- PEG pain and function score (0-10): 7.3 at baseline, 6 at this visit **S**
- PHQ-9: 8 at baseline, 6 at this visit **S**

## Immunizations given today

- Influenza vaccine, 2026-2027 season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and not sedated; pupils equal and normal in size |
| Lungs | Clear |
| Back | Lumbar paraspinal tenderness, unchanged |
| Right ankle | Bony enlargement and reduced motion; no effusion |
| Gait | Steadier with the cane and shoe lift |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Long-term opioid therapy, first taper step** (Z79.891). 60 MME a day with improving function and no sign of opioid use disorder: one prescriber on the prescription drug monitoring program, a consistent urine drug test at intake, and no early refills. **S**
   - Reduce oxycodone to 10 mg three times daily as needed and 5 mg at bedtime as needed, 52.5 MME a day.
   - Next reduction in about a month if pain and function hold; pause if they worsen.
   - Call for yawning, gooseflesh, stomach cramps, diarrhea, or restlessness, which would suggest withdrawal.
   - A lower dose means lower tolerance: never take extra tablets to make up a dose, and keep naloxone at hand.
2. **Chronic post-traumatic back and pelvic pain** (G89.21). PEG 6.0, down from 7.3 at intake; PHQ-9 6, down from 8. **S**
   - Continue duloxetine 60 mg daily, acetaminophen 1 g three times a day, and physical therapy.
   - Weekly cognitive behavioral therapy for chronic pain from today.
3. **Post-traumatic osteoarthritis of the right ankle and foot** (M19.171). Standing tolerance improving with the shoe lift and gel. **S**
   - Continue diclofenac gel.
4. **Vitamin D deficiency** (E55.9). On repletion. **S**
   - Continue cholecalciferol 2,000 units daily.
5. **Immunizations**. Due for this season's influenza vaccine. **S**
   - Influenza vaccine given today.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 6.0, down from 7.3 at intake |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Completed today | 6, down from 8, with item 9 scored 0 |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | Function improving; no sedation, constipation, or falls |
| Medication safety | Taper step | About 10 percent a month for long-term therapy, adjusted to her response | Completed today | 60 to 52.5 MME a day, a 12.5 percent step, the smallest change possible with whole 5 mg tablets; agreed with her |
| Medication safety | Opioid withdrawal symptoms | At each contact after a reduction | Due | First check at next week's visit |
| Medication safety | Opioid use disorder assessment | Before tapering and whenever concerns arise | Completed today | No signs: one prescriber, a consistent urine drug test, no early refills or dose escalation |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Completed today | Checked before today's new prescription: a single prescriber and no sedatives |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake, consistent with the prescribed oxycodone only |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | Confirmed at home and in date last week; reviewed again today |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None |
| Medication safety | Duloxetine tolerance after a dose change | About 2 weeks after each dose change | Completed today | No side effects on 60 mg; blood pressure 114/72 |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Up to date | 22 U/L at intake; recheck at the six-week review |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Unchanged; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | No clinical change |
| Referral | Cognitive behavioral therapy for chronic pain | Weekly | Up to date | Weekly sessions start today |
| Self-management | Exercise program adherence | Every visit | Completed today | Physical therapy twice weekly, one session missed while ill; home exercises daily |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | Recheck in about nine weeks |
| Medication safety | Influenza vaccine | Every season | Completed today | Given today |

## Goal progress

- Improve the PEG score by at least 30% from baseline. In progress; target 2026-10-29. **S**
- Stand at the easel for 30 minutes at a time by the six-week review. In progress; target 2026-10-29. **S**
- First opioid dose reduction, agreed by the patient, without loss of function. In progress; target 2026-10-29. **S**
- Naloxone in the home with a family member trained to use it. Outcome by 2026-09-17: Naloxone nasal spray dispensed; spouse taught at the first visit. **S**

## Medication changes

- Stopped: Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day) **S**
- Started: Oxycodone 10 mg oral tablet, one tablet three times daily as needed for pain **S**
- Started: Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for pain **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017), American College of Physicians (Annals of Internal Medicine)
- VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026), Aether Forge

## Follow-up

- Adult preventive visit next week, with a check for withdrawal. Six-week chronic pain review in two weeks. **S**
- Next scheduled visit 2026-10-22: adult preventive visit. **S**
